| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Thyroid hormone inactivation in gastrointestinal stromal tumors. | N Engl J Med | 2014 | 2.80 |
| 2 | Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. | J Clin Oncol | 2013 | 2.11 |
| 3 | Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. | Am J Surg Pathol | 2012 | 1.83 |
| 4 | Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. | Mol Cancer Ther | 2012 | 1.07 |
| 5 | Aberrant AKT activation drives well-differentiated liposarcoma. | Proc Natl Acad Sci U S A | 2011 | 1.00 |
| 6 | The utility and limitation of single nucleotide polymorphism analysis on whole genome amplified mesenchymal tumour DNA in formalin fixed tumour samples. | Pathology | 2012 | 0.78 |